

**Sterne Kessler
Goldstein Fox**
ATTORNEYS AT LAW



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbalà
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr
Michael V. Messinger

Judith U. Kim
Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Donald R. Banowitz
Peter A. Jackman
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Brian J. Del Buono
Virgil Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Rae Lynn P. Guest

Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gabry L. Longworth
Lori A. Gordon
Nicole D. Dretar
Ted J. Ebersole
Laura A. Vogel
Bryan S. Wade
Aaron L. Schwartz
Shannon A. Carroll*

Wesley W. Jones*
Matthew E. Kelley*
Michelle K. Holoubek*
Marsha A. Rose*

Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Victoria S. Rutherford
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse

Christopher J. Walsh
Liliana Di Nola-Baron
Peter A. Socarras
Jeffrey Mills
Danielle L. Letting

Of Counsel
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

January 25, 2006

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

WRITER'S DIRECT NUMBER:
(202) 772-8764
INTERNET ADDRESS:
CWALSH@SKGF.COM

Art Unit 1624

Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 09/518,501; Filed: March 3, 2000
For: **Novel Phosphorus-containing Prodrugs**
Inventors: Erion *et al.*
Our Ref: 2358.0010002/RWE/CJW

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Supplemental Information Disclosure Statement pleading;
2. Supplemental Information Disclosure Statement Form (1 sheet);
3. Copies of three (3) references (References C115-C117); and
4. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
January 25, 2006
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Christopher J. Walsh
Attorney for Applicants
Registration No. 55,709

CJW/dab
489186_1.DOC
Enclosures



UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Erion *et al.*

Appl. No.: 09/518,501

Filed: March 3, 2000

For: **Novel Phosphorus-containing
Prodrugs**

Confirmation No.: 7608

Art Unit: 1624

Examiner: T. McKenzie

Atty. Docket: 2358.0010002/RWE/CJW

Supplemental Information Disclosure Statement

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on the accompanying IDS Form are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Supplemental Information Disclosure Statement filed on December 20, 2005 in connection with the above-captioned application. Copies of the documents are provided herewith.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication

dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

The Examiner's attention is directed to the prosecution from Dang, Q. *et al.*, U.S. Patent Appl. No. 09/389,698, filed September 3, 1999, now patented as 6,489,476 B1, cited herein as document C118, which is directed to related technical subject matter.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Form, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Christopher J. Walsh
Attorney for Applicants
Registration No. 55,709

Date: January 25, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

485652_1.DOC



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 1 of 1

Application No.	09/518,501
Filing Date	03/03/2000
First Named Inventor	Mark D. Erion
Art Unit	1624
Examiner Name	Thomas C. McKenzie
Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Description	T ¹
	C115	DECHANT, K.L., et al., "Ifosfamide/Mesna. A Review of its Antineoplastic Activity, Pharmacokinetic Properties and Therapeutic Efficacy in Cancer," <i>Drugs</i> 42(3), 428-467 Adis International Limited (1991)	
	C116	JAIN, M., et al., "Sulfonyl-Containing Aldophosphamide Analogues as Novel Anticancer Prodrugs Targeted against Cyclophosphamide-Resistant Tumor Cell Lines," <i>J. Med. Chem.</i> 47, 3843-3852 American Chemical Society (July 2004)	
	C117	Prosecution history of Dang, Q., et al., U.S. Application No. 09/389,698, filed September 3, 1999, now patented as 6,489,476 B1	
	C118		
	C119		
	C120		
	C121		
	C122		
	C123		

489176 1.DOC

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant is to place a check mark here if English language translation is attached.